MYCN and neuroblastoma: The strength of this result relies on the large number of samples in the three neuroblastoma patients’ datasets (837 tumor samples) that have been used to reach this conclusion; this conclusion was further supported by the observation that newborn patients, no MYCN amplification, or low grade stage had a higher expression of TMOD1 and TMOD2 in two independent datasets.